vTv Therapeutics Inc. - Class A (VTVT)
VTVT moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How VTVT actually reacts to news — the realized, point-in-time move the market made, measured across 180 labeled events over the last three years with zero look-ahead.
VTVT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 32% | 124 |
| 30-min | 0.00% | 39% | 138 |
| 60-min | 0.00% | 42% | 151 |
| to close | 0.00% | 49% | 180 |
| Middle 50% of VTVT reactions | -1.69% to +1.72% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 180 |
Half of all vTv Therapeutics Inc. - Class A news events land between -1.69% and +1.72% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VTVT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.30% | 10% | +0.56% |
| Coverage initiations | 42 | 0.00% | 45% | -0.62% |
| Rating reiterations | 16 | 0.00% | 31% | +0.19% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how VTVT ranks against every other measured name →
That’s how VTVT usually reacts — get an email when it moves on news →Email me when VTVT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VTVT's baseline. Nothing else.
Recent VTVT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| iOnctura appoints Paul Sekhri as Chair of its Board of Directors | Press release | GlobeNewswire | +0.00% | -0.76% | |
| vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 | Press release | GlobeNewswire | +0.00% | -2.12% | |
| vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease | Press release | GlobeNewswire | -0.71% | -3.06% | |
| Form 8-K vTv Therapeutics Inc. For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | — | +4.27% | |
| vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026 | Press release | GlobeNewswire | — | -1.48% | |
| vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D) | Press release | GlobeNewswire | — | -1.37% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.52% | -0.23% | |
| vTv Therapeutics to Participate in September Investor Conferences | Press release | GlobeNewswire | -0.15% | +2.61% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +1.66% | |
| Form 10-Q vTv Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.03% | +2.20% | |
| Form 8-K vTv Therapeutics Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | +2.20% | |
| vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +2.53% | +0.49% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.06% | +1.48% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -2.32% | |
| Form 8-K vTv Therapeutics Inc. For: Jun 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.61% | |
| Form DEFA14A vTv Therapeutics Inc. | SEC filing · Form DEFA14A | SEC EDGAR | — | +3.51% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.79% | +0.55% | |
| Form 10-Q vTv Therapeutics Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.18% | +15.34% | |
| Form 8-K vTv Therapeutics Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | +0.18% | +15.34% | |
| Form S-8 vTv Therapeutics Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.18% | +15.34% | |
| vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.18% | +15.34% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | -2.06% | |
| vTv Therapeutics to Participate in Upcoming May Investor Conferences | Press release | GlobeNewswire | +0.00% | -1.86% | |
| Form DEF 14A vTv Therapeutics Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +1.43% | -1.82% | |
| vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.01% | -1.94% | |
| vTv Therapeutics to Participate in the 38th Annual ROTH Conference | Press release | GlobeNewswire | +2.39% | +15.51% | |
| Form 10-K vTv Therapeutics Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -8.69% | |
| Form 8-K vTv Therapeutics Inc. For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -8.69% | |
| vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -8.69% | |
| Form 8-K vTv Therapeutics Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | — | +2.05% | |
| vTv Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.45% | -5.73% | |
| Form 8-K vTv Therapeutics Inc. For: Jan 30 | SEC filing · Form 8-K | SEC EDGAR | — | +8.39% | |
| vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 | Press release | GlobeNewswire | +0.00% | +6.12% | |
| Form 8-K vTv Therapeutics Inc. For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.92% | |
| vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | Press release | GlobeNewswire | +0.00% | -1.29% | |
| Form EFFECT vTv Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -4.94% | |
| Form 10-Q vTv Therapeutics Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | +4.67% | |
| Form 8-K vTv Therapeutics Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | — | +4.67% | |
| vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | +4.67% | |
| vTv Therapeutics Announces New Appointments to its Scientific Advisory Board | Press release | GlobeNewswire | -2.70% | +6.61% | |
| Form S-3 vTv Therapeutics Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -2.92% | |
| vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting | Press release | GlobeNewswire | +3.37% | +2.72% | |
| Form 8-K vTv Therapeutics Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | — | -1.07% | |
| UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | — | +0.71% | |
| vTv Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | — | +4.78% | |
| Form 8-K vTv Therapeutics Inc. For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | +3.75% | +7.92% | |
| vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund | Press release | GlobeNewswire | +3.75% | +7.92% | |
| Form 10-Q vTv Therapeutics Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.21% | |
| Form 8-K vTv Therapeutics Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.21% | |
| vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +0.21% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VTVT section they belong to.
Where else VTVT is measured.
VTVT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIO BLAST PHARMA LTD ORDINARY (ORPN) | 180 | 0.00% | 35% |
| scPharmaceuticals Inc. (SCPH) | 180 | +0.09% | 50% |
| SOL GLOBAL INVTS CORP (SOLCF) | 179 | 0.00% | 49% |
| Heartbeam, Inc. (BEAT) | 178 | -0.55% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is vTv Therapeutics Inc. - Class A's median reaction calculated?
Every labeled VTVT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 180 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of VTVT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VTVT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.